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Background and aims: Annexin-A2 (AnxA2) is an endogenous inhibitor of proprotein convertase sub-
tilisin/kexin type-9 (PCSK9). The repeat-one (R1) domain of AnxA2 binds to PCSK9, blocking its ability to
promote degradation of low-density lipoprotein cholesterol-receptors (LDL-R) and thereby regulate low-
density lipoprotein cholesterol (LDL-C) levels. Here we identify variants in ANXA2 inﬂuencing LDL-C
levels and we determine the molecular mechanisms of their effects.
Results: The ANXA2 single nucleotide polymorphism (SNP) genotype-phenotype association was exam-
ined using the Second-Northwick-Park Heart Study (NPHSII) (n~2700) and the UCL-LSHTM-Edinburgh-
Bristol (UCLEB) consortium (n~14,600). The ANXA2-R1 domain coding-SNP rs17845226 (V98L) associated
with LDL-C, homozygotes for the minor allele having z18.8% higher levels of LDL-C (p ¼ 0.004), and
higher risk of coronary heart disease (CHD) (p ¼ 0.04). The SNP is in modest linkage disequilibrium
(r2 > 0.5) with two intergenic SNPs, rs17191344 and rs11633032. Both SNPs showed allele-speciﬁc
protein binding, and the minor alleles caused signiﬁcant reduction in reporter gene expression (z18%,
p < 0.001). In the expression quantitative trait loci (eQTL) study, minor allele homozygotes have
signiﬁcantly lower levels of ANXA2-mRNA expression (p ¼ 1.36  1005).tein convertase subtilisin/kexin type-9; LDLR, low-density lipoprotein cholesterol-receptor; LDL-C, low-density lipo-
eart Study; UCLEB, UCL-LSHTM-Edinburgh-Bristol consortium; CHRD, cysteine-histidine-rich domain of PCSK9; FAIRE,
ts; CTCF, CTC-binding factor.
enetics, Institute of Cardiovascular Science, University College London, Rayne Building Rm 318, 5 University St, London
iroozy).
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R.H. Fairoozy et al. / Atherosclerosis 261 (2017) 60e68 61Conclusions: Both rs11633032 and rs17191344 SNPs are functional variants, where the minor alleles
create repressor-binding protein sites for transcription factors that contribute to reduced ANXA2 gene
expression. Lower AnxA2 levels could increase plasma levels of PCSK9 and thus increase LDL-C levels and
risk of CHD. This supports, for the ﬁrst time in humans, previous observations in mouse models that
changes in the levels of AnxA2 directly inﬂuence plasma LDL-C levels, and thus implicate this protein as a
potential therapeutic target for LDL-C lowering.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hypercholesterolemia is a major risk factor for atherosclerosis
and coronary heart disease (CHD), most often caused by an indi-
vidual having a greater than average number of common lipid-
raising SNPs. The Global Lipids Genetics consortium (2013) has
identiﬁed 157 novel loci associated with lipid levels, 15 of which are
known to inﬂuence plasma levels of Low Density Lipoprotein
cholesterol (LDL-C) [1]. PCSK9 binds to the epidermal growth factor
domain A (EGF-A) of the LDL-R via its catalytic domain either
intracellularly or at the cell surface [2]. Once the PCSK9≡LDL-R
complex is formed, it is internalised by endocytosis and degraded
[3,4]. Gain-of-function mutations in PCSK9 strongly promote LDL-R
degradation and lead to FH, whereas loss-of-function mutations of
PCSK9 are unable to enhance LDL-R downregulation and therefore
result in lower levels of LDL-C [5]. This suggests that lowering
PCSK9 will protect against atherosclerosis and CAD.
AnxA2 has been identiﬁed in animal and cellular models as an
endogenous inhibitor of PCSK9 and thus inﬂuences LDL-Receptor
and plasma cholesterol levels [6e8]. AnxA2 is widely expressed,
and in mice, high AnxA2 levels are found in the lung, pancreas,
colon, ileum and adrenal tissues. In contrast, spleen, testis, kidney
and liver express low AnxA2 levels [8]. AnxA2 belongs to the
conserved annexin family of phospholipid and calcium-binding
proteins. AnxA2 exists as a monomer, yet the majority of AnxA2
forms a heterotetramer with the S100 protein p11 (S100A10) both
in intra- and extracellular locations [9,10]. Inside cells, AnxA2 reg-
ulates a spectrum of functions related to membrane organization
and trafﬁcking [9,11,12]. In plasma, in particular on the surface of
endothelial cells, the AnxA2/p11 complex is involved in vascular
ﬁbrinolysis [9,10]. In addition, AnxA2 has several other extracellular
AnxA2 activities [13]. Most relevant to this study, AnxA2, either as
monomer or complexed with p11, is involved in cholesterol meta-
bolism through the binding of its R1-domain to the cysteine-
histidine-rich domain (CHRD) of PCSK9 at the cell surface, which
inhibits PCSK9-mediated degradation of LDL-R. This helps to
maintain LDL-R levels at the cell surface with the subsequent
greater clearance of LDL-C [6,8]. An in vitro study reported that a
mutation Q554E in the CHRD of PCSK9 increased the binding af-
ﬁnity between PCSK9 and AnxA2, which in turn lead to a loss-of-
function of PCSK9 towards LDL-R degradation [6]. This suggested
an involvement of AnxA2 in the regulation of LDL-C levels, and
subsequent in vivo studies in AnxA2 knockout mice identiﬁed
higher levels of plasma PCSK9 and LDL-C, which correlated with a
reduction in LDL-R protein levels, mostly in extrahepatic tissues [8].
Moreover, adenoviral AnxA2 overexpression in mouse liver signif-
icantly increased hepatic LDL-R levels [8]. Therefore, we hypothe-
sized that a mutation in the ANXA2 R1-domain could also affect
LDL-C levels.
The ANXA2 locus is located on chromosome 15q22.2 and con-
sists of 13 exons [14], and its expression is regulated at both the
transcriptional and translational levels [9]. The R1-domain of
ANXA2 is encoded by exons 4e6, which has eight reported SNPs
including one missense variant rs17845226, which changes Valineto Leucine at position 98. This SNP was selected for further study
because it has been validated by HapMap and the 1000 Genome
Project, and is the only SNP that has a minor allele frequency
(MAF)  0.05. Also, in a preliminary study including only 43 sub-
jects, this SNP was implicated to affect circulating PCSK9 levels [8],
but a thorough analysis of its association with LDL-C and CHD in
larger cohorts has not yet been performed. To elucidate the mo-
lecular mechanism behind the effect seen, the linkage disequilib-
rium (LD) of this SNP with others at the locus was examined, and
bioinformatics and in vitro functional assays were used to deter-
mine the likely functional SNPs at this locus.
2. Materials and methods
2.1. Study cohorts
The Second-Northwick-Park Heart Study (NPHSII) consists of
3052 (with DNA available n~2700) healthy middle-aged men
(50e61 years) who were recruited in 1989 from nine general
medical practices in the United Kingdom (UK) and followed for up
to 15 years. The UCL-LSHTM-Edinburgh-Bristol (UCLEB) con-
sortium consists of 30,000 participants from 12 well-established
UK studies (participants are almost exclusively of European
ancestry). Further details of studies background can be found in
Supplementary Materials.
2.2. Genotyping and statistics
The ANXA2 SNPs rs17845226 and rs17191344were genotyped in
the NPHSII study using Applied Biosystems TaqMan SNP Geno-
typing Assay. The assay mix was added over 5 ng dry DNA and
thermocycled as per the manufacturer's instructions, and ﬂuores-
cence detected with ABI 7900HT. Statistical analyses for both
NPHSII and UCLEB are explained in details in Supplementary
Materials.
2.3. Bioinformatics
Multiple algorithmswere used to predict the impact of missense
mutations (ANXA2-R1 rs17845226 SNP V98L) on protein structure
and function: Sorting Intolerant Form Tolerant (SIFT), Polyphen-2
V2, and Mutation Assessor V3 [15]. The 1000 Genomes Project
data and the Broad Institute's HaploReg V4.1 [16e18] were used to
identify variants in strong (r2  0.8) and modest (r2  0.4) linkage
disequilibrium (LD) with the ANXA2-coding SNP rs17845226. These
variants were examined for regulatory annotations from the
ENCODE Project [19,20] and the RoadMap Epigenomics data [21],
To visualize variant location, the UCSC Genome Browser was used
[22]. The ElDorado tool (Genomatix Software GmbH, Germany) [23]
was used to select variants with only strong motif changes
(thresholds had core similarity of 1 and matrix similarity of >0.8).
Further details of bioinformatics analyses can be found in
Supplementary Materials.
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EMSAs were used to investigate the effect of variants' genotype
on DNA-protein binding. Nuclear extract for EMSA was obtained
from hepatocarcinoma Huh7 cells as described in Ref. [24]. Bio-
tinylated allele-speciﬁc probes for the three selected SNPs were
incubated with a Huh7 cell nuclear extract (probe sequences in
Supplementary Table 1). EMSA was performed as described in
Ref. [25].2.5. Luciferase reporter assay
To generate luciferase-constructs, The ANXA2 intergenic SNP
sequences encompassing the SNP alleles [rs17191344 A > G (776
bp) and rs11633032 G > A (593 bp) (primer sequences are shown in
Supplementary Table 4) were individually inserted into the
enhancer site of the pGL3-promoter luciferase reporter vector
(Promega) after the SV40 polyadenylation signal according to the
manufacturer's instructions. Both reference allele and alternative
allele luciferase-constructs were transfected into Huh7 cells along
with the Renilla luciferase pRL-TK as co-transfectant control. The
ﬁreﬂy and renilla luciferase activity was detected using Promega's
Dual-Luciferase Reporter Assay System according to the manufac-
turer's instructions.3. Results
3.1. Bioinformatics analysis
The R1-domain of ANXA2 is encoded by exons 4e6, which hasFig. 1. Genome-wide maps of chromatin state of ANXA2 rs17191344 SNP.
Schematic representation of the ANXA2 rs17191344 chromatin status (shttps://genome-euro
marker includes seven cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, and NHL
the references to colour in this ﬁgure legend, the reader is referred to the web version of teight reported SNPs, including one missense variant rs17845226.
The ANXA2-R1 rs17845226 SNP is located in exon 6 of the gene and
causes a Valine/Leucine amino acid change; the MAF is 12% in Eu-
ropean populations (1000 Genomes Project Phase 3). Although the
altered amino acid (Valine) is highly conserved in vertebrate spe-
cies (Supplementary Fig. 1), the change is predicted to be non-
pathogenic by the SIFT, Polyphen-2, and MutationTaster predict-
ing tools.
The ANXA2-R1 rs17845226 SNP has modest LD (r2  0.4) with
34 SNPs, all located downstream of the ANXA2 gene-coding re-
gion in the long intergenic region between two genes, FOXB and
ANXA2 on chromosome 15, and near the RORA and LIPC loci,
which play roles in lipid metabolism and atherosclerosis
(Supplementary Fig. 2). Out of 34 SNPs, the rs17191344 SNP
(r2 ¼ 0.45, MAF ¼ 16%) has the strongest regulatory proﬁle,
where the SNP is highly conserved and has strong enhancer signs
in 13 tissues including the liver. The SNP is located in an open
chromatin region, where the markers of DNAase I, FAIRE, and
transcription factor binding are strong (Fig. 1). Both ENCODE and
ElDorado data show that the G allele of the rs17191344 SNP
creates a binding site for CTCF, and this SNP also changes a YY1
binding motif. The YY1 transcription factor can associate with
CTCF and regulate gene expression [26]. The rs17191344 SNP has
strong LD (r20.8) with 66 SNPs, all in the intergenic region
(Supplementary Fig. 3), of which SNPs rs11633032 and
rs12900101 (MAF ¼ 17%) are predicted to bind to regulatory
transcription factors as shown in the ElDorado data. These two
SNPs are also in modest LD with the ANXA2-coding SNP
rs17845226 (r2 ¼ 0.40 and 0.41, respectively)..ucsc.edu). The area of interest is highlighted in light-blue. Promoter/enhancer histone
F). FAIRE, formaldehyde assisted isolation of regulatory elements. (For interpretation of
his article.)
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3.2.1. Association of ANXA2 SNPs rs17845226 and rs17191344 with
lipid traits and CHD in NPHSII
The association of rs17845266 and rs17191344 with LDL-C and
CHD was investigated in the NPHSII cohort. Baseline study char-
acteristics are summarized in Supplementary Table 5. The minor
allele frequency of rs17845266 in NPHSII was 0.13 while the
rs17191344 minor allele frequency was 0.145, both similar to that
seen in European populations.
rs17845226 showed a signiﬁcant association with LDL-C and
CHD under both modes of inheritance (recessive and additive).
Table 1 shows that individuals who are homozygous for the minor
allele (A) had signiﬁcantly higher levels of total cholesterol
(TC) z8.4% and LDL-C z18.8% (p ¼ 0.01 and 0.004, respectively),
and had a signiﬁcantly higher risk of CHD (HR (95% CI): 2.17
(1.03e4.60), p ¼ 0.04)). The most likely cause of the observed CHD
association is that it is due to these subjects having a higher level of
LDL-C, and when the CHD association was adjusted for LDL-C, the
effect was no longer statistically signiﬁcant. This suggests that the
main mechanism for this SNP to be inﬂuencing risk of CHD is via its
effect on LDL-C levels.
The modest LD SNP rs17191344 shows the same trend as the
lead coding SNP (Table 1), where individuals who carried two
copies of the minor allele have higher levels of LDL-C (p¼ 0.05) and
a higher risk of CHD [HR (95% CI) ¼ 1.86 (1.02e3.41), (p ¼ 0.05).
Table 2 and Supplementary Fig. 4 show the combined genotype
association of rs17191344 and rs17845226, where LDL-C levels in-
crease per minor allele of both SNPs. The individuals who have two
copies of the minor allele of both SNPs (G and A respectively) had
signiﬁcantly higher levels of LDL-C (p ¼ 0.007) and over two-fold
higher risk of CHD [HR (95% CI) ¼ 2.75 (1.18e6.39), (p ¼ 0.019)].
Stepwise models indicated that only those with two copies of the
minor allele of both SNPs had signiﬁcantly raised levels for the
lipids: TC [b(se) ¼ 0.482 (0.22), r2 ¼ 0.002, p ¼ 0.029] and LDL-C
[b(se) ¼ 0.649, r2 ¼ 0.004, p ¼ 0.008] (Supplementary Table 6).
This conﬁrms the result from Table 2, where only the GG/AA group
has signiﬁcantly different levels from the other groups for these
lipid traits. For CHD, the GG/CC group had signiﬁcantly higher risk
compared to the other groups [HR (95% CI) ¼ 6.53 (1.62e26.27),
p ¼ 0.008].3.2.2. Association of ANXA2 intergenic SNPs with lipid traits and
CHD in the UCLEB consortium
The UCLEB consortium, comprising ~14,600 subjects from theTable 1
An association between rs17845226 and rs17191144 genotype and lipid risk factors and
Genotype rs17845226 (Val98Leu)
CC (n ¼ 1868) CA (n ¼ 561) AA (n ¼ 34) p-valuea p
TC (mmol/L) 5.73 (1.00) 5.80 (1.04) 6.21 (1.05) 0.014 0
LDL-C (mmol/L) 3.08 (0.99) 3.16 (1.04) 3.66 (0.94) 0.006d 0
HDL-C (mmol/L) 0.81 (0.24) 0.80 (0.26) 0.74 (0.23) 0.456 0
TG (mmol/L)c 1.74 (1.25e2.54) 1.7 (1.22e2.65) 1.74 (1.22e2.91) 0.970 0
CHD risk by genotype
No. without CHD (%) 1672 (75.8) 507 (23.0) 26 (1.2) e e
No. with CHD (%) 196 (76.0) 54 (20.9) 8 (3.1) e e
HR (95% CI) Model 1 1.00 0.93 (0.68e1.26) 2.17 (1.03e4.60) 0.578e 0
HR (95% CI) Model 2 1.00 0.84 (0.59e1.20) 1.25 (0.49e3.20) 0.573 0
d and e Deviation from a dominant model p ¼ 0.051.
d and e Deviation from a dominant model p ¼ 0.021.
Model 1: age and practice adjusted; Model 2: adjusted for age, practice and LDL-C.
a p-value according to additive model.
b p-value according to recessive model.
c Median [IQR].UK general population, was used for replication. Study character-
istics are summarized in Supplementary Table 7. Wewere unable to
impute rs17191344, but two SNPs rs11633032 (G > A) and
rs12900101 (C > G) [having a strong LD (r2 ¼ 0.98) with
rs17191344] had a high average value of imputation genotype data
from the Metabochip (r2 ¼ 0.63) (Supplementary Table 8).
As shown in Supplementary Table 9 and Supplementary Fig. 5,
the minor alleles of rs11633032 and rs12900101 were associated
with signiﬁcantly higher levels of LDL-C in men [effect
size ¼ 0.21 mmol/L, p ¼ 0.018 and 0.19 mmol/L, p ¼ 0.036 respec-
tively for the recessive model], but not inwomen, whichmay partly
be due to different sample sizes between the genders. To assess
whether there the effect is different between the sexes, we tested
the estimated difference between sexes, and no difference was
found (Supplementary Table 10). Overall, the minor alleles of
rs11633032 and rs12900101 were associated with signiﬁcantly
higher levels of LDL-C [effect size ¼ 0.16 mmol/L, p ¼ 0.029 and
0.143 mmol/L, p ¼ 0.048 respectively for the recessive model] with
similar effects in both genders (Supplementary Table 9). This result
conﬁrms the results seen above in the NPHSII subjects, where
subjects are men only.3.3. Allele-speciﬁc protein binding of ANXA2 intergenic SNPs in
Huh7 cells
EMSA was performed to determine whether the three ANXA2-
intergenic SNPs within potential regulatory elements were able to
affect DNA-protein interactions. Two SNPs, rs11633032 and
rs17191344, demonstrated differential protein binding by allele
(Fig. 2). The rs11633032 major G allele bound to proteins or com-
plexes of proteins, whereas the risk A allele did not show allele-
speciﬁc protein binding. In contrast, the risk G allele of the
rs17191344 SNP bound strongly to proteins.
MC-EMSA was performed to characterise the DNA-protein
interaction for the major G allele of the rs11633032 SNP. The re-
sults showed that the G allele speciﬁc-bands were competed out by
cocktail 1 (Supplementary Fig. 6A). Then, when each competitor of
cocktail 1 was run individually, the G allele speciﬁc-bands were
competed out by addition of the GATA and Egr1 consensus se-
quences (Supplementary Fig. 6B).
The bioinformatics analysis for the rs17191344 SNP suggests
that the risk allele of the SNP is a site for CTCF protein binding.
Comparing the CTCF-binding motif to the genomic sequence
around the rs17191344 revealed that theymatched upwell, and the
presence of the risk G allele of the SNP strengthened the bindingCHD risk in the NPHSII cohort.
rs17191344
-valueb AA (n ¼ 1956) AG (n ¼ 659) GG (n ¼ 57) p-valuea p-valueb
.007 5.72 (1.01) 5.74 (1.03) 5.96 (1.04) 0.205 0.085
.003 3.09 (1.00) 3.09 (1.03) 3.38 (1.03) 0.302 0.051
.201 0.81 (0.24) 0.79 (0.25) 0.81 (0.26) 0.494 0.786
.648 1.73 (1.24e2.53) 1.76 (1.25e2.74) 1.62 (1.12e2.56) 0.465 0.604
1749 (73.5) 585 (24.6) 45 (1.9) e e
207 (70.7) 74 (25.3) 12 (4.1) e e
.043 1.00 1.10 (0.83e1.44) 1.86 (1.02e3.41) 0.113 0.052
.60 1.00 0.98 (0.72e1.34) 1.29 (0.60e2.79) 0.787 0.504
Table 2
The rs17191344 and rs17845226 SNPs combined genotype association with lipids traits and CHD in the NPHSII cohort.
rs17191344 rs17845226 Lipids CHD
N TC (mmol/L) p-value LDL-C (mmol/L) p-value N % (N) with CHD HR (95% CI) p-value
AA CC 1658 5.73 (1.00) e 3.09 (0.99) e 1658 10.7 (177) 1.00 e
CA 75 5.81 (1.05) 0.49 3.26 (1.06) 0.21 75 6.7 [5] 0.53 (0.21e1.33) 0.18
AA 3 5.57 (0.45) 0.78 3.18 (0.72) 0.88 3 0 (0) e e
AG CC 137 5.67 (0.97) 0.49 2.97 (1.00) 0.21 137 12.4 [17] 1.32 (0.79e2.20) 0.29
CA 443 5.78 (1.04) 0.33 3.13 (1.04) 0.48 443 10.6 (47) 1.03 (0.74e1.43) 0.88
AA 9 6.32 (0.92) 0.08 3.63 (1.08) 0.15 9 22.2 [2] 3.17 (0.78e12.92) 0.11
GG CC 4 6.18 (0.36) 0.38 3.72 (0.77) 0.28 4 50.0 [2] 8.60 (2.09e35.34) 0.003
CA 23 5.90 (0.94) 0.43 3.22 (1.04) 0.56 23 13.0 [3] 1.35 (0.43e4.26) 0.604
AA 21 6.22 (1.17) 0.025 3.75 (0.96) 0.007 21 28.6 [6] 2.75 (1.18e6.39) 0.019
Adjusted for age and practice.
There were no signiﬁcant SNP  SNP interactions. TC p ¼ 0.75, LDL-C p ¼ 0.83, CHD p ¼ 0.27.
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competed out with 11 different isoforms of CTCF [27]. The results
showed that the rs17191344 G allele speciﬁc bands were competed
out by at least three isoforms of CTCF (Supplementary Fig. 7B),
suggesting that CTCF is the protein that binds to the sequence
around the G allele of the SNP.3.4. Effect of rs17191344 and rs11633032 on reporter gene
expression
Luciferase reporter assays were performed to assess whether
the rs17191344 and rs11633032 SNPs genotype affect gene
expression. The ANXA2 SNPs rs11633032 (593 bp) and rs17191344
(776 bp) fragments containing either allele of the SNP was inserted
downstream of the luciferase gene in the pGL3-promoter vector
(Fig. 3A). The inserted fragment in the pGL3-promoter vectorFig. 2. DNA binding properties of ANXA2-intergenic SNPs.
Conventional EMSA analysis of the ANXA2-intergenic SNPs (rs12900101, rs11633032 and rs17
by the allele competitor probe. The minor allele of rs17191344 has allele-speciﬁc binding a
bands are indicated by arrows and (*) indicates minor allele.resulted in a decrease in expression compared to the control vector
for both alleles of rs11633032 and rs17191344 (Fig. 3B). However,
the presence of minor alleles caused approximately 18% further
signiﬁcant decreases of gene expression in rs11633032
(p¼ 9.1 104) and rs17191344 (p¼ 2.7 104). This suggests that
the sequences around rs11633032 and rs17191344 are sites for
repressor protein binding.3.5. Expression quantitative trait loci (eQTL) analysis
To determine whether ANXA2 intergenic SNPs were associated
with altered gene expression in vivo, we ﬁrst used the publicly
available gene expression data set GTEx. The four genes (FOXB,
ANXA2, RORA and LIPC) near the SNPs were tested in GTEx, but no
signiﬁcant association was found between the SNPs genotype and
gene expression in the liver, whole blood or coronary artery191344). The major allele of rs11633032 has allele-speciﬁc binding that is competed out
t two positions, which are competed out by the allele competitor probe. Allele speciﬁc
Fig. 3. ANXA2-intergenic SNPs luciferase activity in the Huh7 cell line.
(A) A map of the pGL3-promoter constructs showing the location of the added SNP fragment of rs11633032 (585 bp) and rs17191344 (767 bp). (B) The luciferase reporter assays
showing relative expression of ANXA2-intergenic SNPs-luciferase-enhancer-constructs (sequence has SNP of interest inserted into enhancer site of the vector) relative to the control
(pGL3-promoter vector).
R.H. Fairoozy et al. / Atherosclerosis 261 (2017) 60e68 65(Supplementary Fig. 8). However, subjects with one copy of the risk
allele for the rs11633032 had lower expression of ANXA2 in all three
tissues (effect size 0.062 and 0.039, 0.20 respectively), but this
effect was not statistically signiﬁcant (p > 0.05) due to the small
sample size, with only three-six subjects being homozygous for the
minor allele. However this effect is conﬁrmed in the latest GTEx
data, which showed the rs11633032 minor allele was associated
with signiﬁcantly reduced ANXA2 expression in the tibial artery
sample (effect size0.177, p¼ 2.9 1006, N¼ 285) under additive
model.
To examine this further, the ASAP database was used. This
showed low levels of ANXA2 expression in liver tissue, with again
the rs11633032 SNP risk A allele being associated with reduced
expression level of ANXA2 (p ¼ 0.075) (Supplementary Fig. 9), but
with no other nearby gene including LIPC. To further verify these
ﬁndings, we used the publicly available eQTL meta-analysis for
lipid-regulation [28] and found the proxy SNP rs9920796
(r2 ¼ 0.736) was signiﬁcantly associated with lower ANXA2-mRNA
expression levels in blood (Z-score ¼ 4.35, p ¼ 1.36  1005).
Overall, these ﬁndings suggest that the ANXA2-intergenic SNPs
rs11633032 and rs17191344 are sites for repressor protein binding
that reduces the expression level of the gene.
4. Discussion
Biological studies in mice have recently supported cell culture
studies that implicate AnxA2 in the prevention of PCSK9-mediated
degradation of LDL-R [6,8]. AnxA2 mediates this inhibitory effect
via the interaction of its R1-domain with the CHRD of PCSK9.
Therefore, we hypothesized that a mutation in the ANXA2 R1-
domain could affect LDL-C levels in humans. We looked at SNPs
in the R1-domain and the rs17845226 missense variant Val98Leu
was selected for further analysis, as this variant has previously been
associated with lower circulating PCSK9 levels [8] and because the
MAF in the European population is high at 13%. Using genotype-
phenotype analysis, we found that this missense mutation had arecessive effect on LDL-C levels. However, in silico tools predicted
this SNP to be non-pathogenic, suggesting it may simply be acting
as a marker for a functional SNP elsewhere at the locus. Using
bioinformatics, genotype-phenotype analysis, and evidence from
differential protein binding and allele-speciﬁc gene expression, we
identiﬁed two candidate SNPs in the ANXA2 cis-regulatory region
(rs17191344 and rs11633032) also associated with LDL-C and the
risk of CHD, and showed that these SNPs affect ANX2A gene
expression via alterations in transcription factors that bind to al-
leles of the SNPs. This work identiﬁes for the ﬁrst time with sta-
tistical signiﬁcance in humans the observations in cell culture and
AnxA2 knockout mice that changes in the levels of AnxA2 directly
inﬂuence plasma LDL-C levels, and thus implicates this protein, and
the pathway in which it operates, as a potential therapeutic target
for LDL-C lowering.
The effect on LDL-C levels and CHD risk associated with these
ANXA2 variants is recessive, with signiﬁcantly higher levels seen
only in those carrying two copies of the minor allele. If the Leucine
variant is indeed less active, the mechanism of this effect may
depend on the fact that AnxA2 exists as a dimer with two R1-
domains, and thus in an individual heterozygous for the variant,
if one of the two alleles carried is less effective, the other is func-
tional and is still able to bind to PCSK9. However, if both inherited
alleles are less effective in their ability to interact with PCSK9, this
may allow PCSK9 to act on LDL-R. However, the Val98Leu SNP may
simply be acting a as marker for SNPs affecting gene expression,
and to attempt to disentangle this, we assessed the cholesterol
levels and risk of CHD for these individuals with different combi-
nations of genotypes of the Val98Leu SNP rs17845226 with the cis-
regulatory SNP rs17191344 showing modest LD (r2 ¼ 0.45). It was
found that subjects carrying two copies of the minor allele for both
SNPs had the highest LDL-C levels and risk of CHD, but, while
numbers are small, subjects carrying either of the minor alleles had
modestly elevated cholesterol levels and CHD risk, suggesting that
both the amino-acid change and the intronic SNPs are functional.
Although we reported that the intergenic SNPs did not display a
R.H. Fairoozy et al. / Atherosclerosis 261 (2017) 60e6866signiﬁcant difference in cholesterol levels between sexes, women
appeared to be less affected by these variants. Several studies have
suggested that sex and age have an impact on PCSK9 concentration
and consequently LDL-C [29].
In our study, bioinformatics was particularly helpful to select
candidate SNPs for functional studies. The Val98Leu SNP has
modest LD with 34 SNPs, all located downstream of the ANXA2
gene-coding region in the long intergenic region. Such regions
often have a role in gene regulation by interacting with chromatin-
modifying complex proteins [30]. Regulation data from ENCODE
and RoadMap Epigenomics were used to evaluate these 34 variants
for their regulatory potential, and a shortlist of three potentially
functional variants identiﬁed (rs17191344, rs11633032 and
rs12900101).
These predictions were conﬁrmed by in vitro assays. Using
EMSA, rs17191344 and rs11633032, showed allele-speciﬁc protein
binding, with a protein binding strongly to the protective G allele of
rs11633032, while rs17191344 showed a strong allele-speciﬁc
binding to the G risk allele. The luciferase reporter assay was
used to assess the mechanism and action of the SNPs and evaluate
how different protein binding may affect gene expression. It was
found that the minor allele of both SNPs rs11633032 and
rs17191344 reduced the gene expression. Such lower gene
expression in carriers of the risk A allele of rs11633032 was
conﬁrmed using human expression data from GTEx, ASAP and from
the large eQTL meta-analysis. Taken together, these data strongly
suggest that transcriptional repressor proteins binding to the
sequence around the minor alleles of SNPs rs11633032 and
rs17191344 and thus lead to reduced ANXA2-mRNA expression and
protein levels. When expressed at low levels, all available AnxA2
may be “moped up” by other high-afﬁnity, high-abundance, AnxA2
binding proteins in plasma such as plasminogen or tPA [10] or even
membrane phospholipids. This would leave no available AnxA2 to
interact with PCSK9, and allow PCSK9 to bind to LDL-R, leading to
lower levels of LDL-R receptors in the liver and consequently,
increased plasma LDL-C levels.
Several potential transcriptional factors involved in the regula-
tion of AnxA2 expression levels were identiﬁed. MC-EMSA sug-
gested that the GATA and Egr1 proteins bind to the sequence
around the G allele of rs11633032, and CTCF binds to the sequence
in the presence of the G allele of rs17191344. The protein family
GATA comprises six members (GATA1 to GATA6) all of which have a
highly conserved double zinc ﬁnger domain that mediates binding
to DNA and to co-factors to regulate gene expression in a highly
tissue-restricted fashion. GATA recruits chromatin remodelling
complex and mediates either repression or activation of target
genes [31,32]. The Egr1 is a nuclear factor that regulates gene
expression in a tissue-restricted manner, through its binding to
other regulatory transcription factors [33]. GATA and Egr1 could be
part of a chromatin remodelling complex, which as a complex
mediates gene expression. The CTCF is considered an insulator
element and plays a critical role in transcriptional regulation. There
are two possible functions of an insulator in gene regulation. First, it
binds to DNA-regulatory sequences in the promoter-proximal re-
gions where it competes for enhancer-bound activators and pre-
vents the activation of downstream promoters [27,34]. In addition,
insulators could be involved in gene regulation by facilitating the
formation of separate loop domain structures, which prevent an
enhancer on one loop from contact a promoter on a different loop
[35,36]. Despite the identiﬁcation of abovementioned transcription
factors GATA, Egr1 and CTCF to bind AnxA2 mRNA in vitro, future
work will need to validate their contribution to the regulation of
AnxA2 expression levels in hepatic cell lines. In particular, over-
expression or silencing of the transcription factor CTCF could pro-
vide further insight if rs11633032 and rs17191344 canmodulate thededuced repressor functions of this transcription factor.
4.1. Limitations
We have no data that addresses directly whether or not the
Val98Leu change is affecting AnxA2 function. One study [8] has
presented preliminary evidence that V98L does not affect the
binding afﬁnity of AnXA2 for PCSK9, but it is associated with lower
circulating PCSK9 and may be resulting in lower LDL levels. The
authors suggest that further studies are needed to examine
whether this mutation modiﬁes the function of PCSK9 or has
downstream consequences on LDL-R activity. It may be that the
coding sequence change could be a site for a transcriptional regu-
latory element [37,38]. The sequence around the coding SNP
rs17845226 is located in a DNAse I hypersensitive domain, thus it
may be a site for positive-acting regulatory sequences, which could
interact with intergenic functional SNPs and the ANXA2 promoter
to initiate gene transcription. A second limitation is that it was not
possible to impute the genotype in UCLEB for rs17845226, although
the examined SNPs were imputed with a reasonable degree of
precision (r2 ¼ 0.63). Since the SNPs were associated with LDL-C
levels in the UCLEB cohort, it is possible that with wet-lab geno-
typing the effect sizes seen would have been larger, but this
imprecision in imputationwould is highly unlikely to have resulted
in a false positive result.
The in vitro data also has limitations. Our data show that a
regulatory element near to rs11633032 and rs17191344 SNPs acts as
a repressor of ANXA2 expression in the liver cell line, as it is a major
site for LDL-C clearance from the plasma [39], but we could not
determine whether or not it also inﬂuenced gene expression in
other tissues. AnxA2 levels in liver are generally considered low [8],
but in line with our studies using HuH7 as model system, stable
knockdown of AnxA2 expression in HuH7 resulted in PCSK9
upregulation and a marked reduction in LDL-R levels [40]. How-
ever, this may not be representative for all human hepatocellular
carcinoma cell lines as AnxA2 depletion in HepG2 cells, which ex-
press approximately 5-fold less AnxA2 mRNA compared to HuH7,
did not alter PCSK9 or LDL-R protein expression. Moreover, in this
study a potentially new mechanism, suggesting a role for AnxA2 in
the translational control of PCSK9 protein levels, was proposed [40].
The overall contribution of transcriptional, as described here, and
translational regulation of AnxA2 expression affecting PCSK9
maturation and protein levels not only in the extracellular space,
but also during PCSK9 synthesis and secretion has yet to be
determined in vivo.
To demonstrate the functional role of SNP, we used two in vitro
assays namely EMSA and luciferase, using the hepatoma cell line
Huh7, which can only approximate the actual gene expression
occurring in vivo in the liver, where open chromatin structure and
epigenetics have a potential role in gene regulation. In particular,
the selected enhancer fragments cannot accurately reﬂect the
natural in vivo environment, where chromatin modiﬁcation and
interaction play essential roles in mediating gene expression. We
also used the pGL3-promoter vector, since it proved impossible to
obtain a cloned sequence of the ANXA2 promoter due the presence
of a repetitive sequence in the promoter which prevented DNA
ampliﬁcation. It is also possible that the enhancer SNPs may affect
expression of other distal genes at the locus promoters, although it
seems unlikely that alterations in the levels of these genes could be
having the effect on LDL-C seen here, with the ASAP data showing
no evidence for a strong association of the SNP on expression of
other nearby genes.
The ANXA2 cis-regulatory SNPs, rs11633032, rs17191344 and
rs12900101 that we studied have strong LD with 64 SNPs, all in the
intergenic region. Here we used ENCODE and a summary tool,
R.H. Fairoozy et al. / Atherosclerosis 261 (2017) 60e68 67HaploReg V4, to select potential functional candidate SNPs. How-
ever, the other LD SNPs we did not examine may have a role in
transcription regulation. This kind of limitation is unavoidable
because there is no conclusive tool to rank likelihood functionality
of non-coding variants.
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